The utility of OCA was further strengthened by the successes of the FLINT cohort, a phase IIb NAFLD intervention study, in which the FXR agonist reduced all factors of the NAFLD activity score in concert [78]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.